Details

Autor(en) / Beteiligte

• Morillo, Carlos A
• Marin-Neto, Jose Antonio
• Avezum, Alvaro
• Sosa-Estani, Sergio
• Rassi, Anis
• Rosas, Fernando
• Villena, Erick
• Quiroz, Roberto
• Bonilla, Rina
• Britto, Constança
• Guhl, Felipe
• Velazquez, Elsa
• Bonilla, Laura
• Meeks, Brandi
• Rao-Melacini, Purnima
• Pogue, Janice
• Mattos, Antonio
• Lazdins, Janis
• Connolly, Stuart J
• Yusuf, Salim

Titel

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

Ist Teil von

• The New England journal of medicine, 2015-10, Vol.373 (14), p.1295-1306

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In this double-blind, placebo-controlled trial involving 2854 patients with Chagas' cardiomyopathy, no clinical benefit was found with 2 to 3 months of benznidazole therapy during 5 years of followup. Chagas’ disease is the third most common parasitic disease globally, after malaria and schistosomiasis. 1 Chagas’ cardiomyopathy is the most common form of nonischemic cardiomyopathy and one of the leading causes of complications and death in Latin America. 2 An estimated 6 million to 7 million persons are infected, and 36,800 new cases occur each year. Chagas’ cardiomyopathy develops in approximately 25% of patients infected with Trypanosoma cruzi . 3 – 5 Chagas’ disease has two phases: acute and chronic. Acute infection is usually a self-limited febrile illness. 6 In the chronic phase, cardiac or digestive complications develop in approximately one third of patients two . . .